# US 2026/0085086 A1 · Carbamate nucleotide analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085086 A1
- Document ID: US20260085086A1
- Status: Published application
- Kind: A1
- Application number: 19/335,913
- Filed: 2025-09-22
- Published: 2026-03-26
- Earliest claimed: 2024-09-23
- Assignees: Singular Genomics Systems, Inc.
- Applicants: Singular Genomics Systems, Inc.
- Inventors: Ronald GRAHAM
- Web page: https://patentgrep.com/patent/US20260085086A1

## CPC

- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 19/073: with 2-deoxyribosyl as the saccharide radical
- C07H 23/00: Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12 (esters with inorganic acids C07H11/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Disclosed herein, inter alia, are compounds and methods of making and using thereof.

## Claims

### Claim 1

A compound, or a salt thereof, having the formula:
B1 is a nucleobase;
R1 is a polyphosphate moiety, monophosphate moiety, 5′-nucleoside protecting group, or —OH;
R2 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2,
—CHI2, —CH3Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH,
—SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H,
—NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2,
—OCHI2, —OCHF2, —OCH3Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a polymerase-compatible cleavable moiety;
L1 is a bond or a covalent linker; and
R3 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2,
—CHI2, —CH3Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH,
—SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H,
—NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2,
—OCHI2, —OCHF2, —OCH3Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.

### Claim 2

A compound, or a salt thereof, having the formula:
wherein,
B2 is a divalent nucleobase;
R1 is a polyphosphate moiety, monophosphate moiety, 5′-nucleoside protecting group, or —OH;
R2 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2,
—CHI2, —CH3Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH,
—SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H,
—NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2,
—OCHI2, —OCHF2, —OCH3C1, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a polymerase-compatible cleavable moiety;
L1 is a bond or a covalent linker; and
R3 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2,
—CHI2, —CH3Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH,
—SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H,
—NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2,
—OCHI2, —OCHF2, —OCH3Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R4 is a detectable moiety; and L100 is a divalent linker.

### Claim 3 (depends on 1)

The compound of claim 1, wherein L1-R3 is:

### Claim 4 (depends on 1)

The compound of claim 1, wherein L1-R3 is:

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2 is hydrogen.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is a monophosphate moiety or polyphosphate moiety.

### Claim 7 (depends on 1)

The compound of claim 1, wherein B1 is a cytosine or a derivative thereof, guanine or a derivative thereof, adenine or a derivative thereof, thymine or a derivative thereof, uracil or a derivative thereof, hypoxanthine or a derivative thereof, xanthine or a derivative thereof, 7-methylguanine or a derivative thereof, 5,6-dihydrouracil or a derivative thereof, 5-methylcytosine or a derivative thereof, or 5-hydroxymethylcytosine or a derivative thereof.

### Claim 8 (depends on 1)

The compound of claim 1 wherein B1 is

### Claim 9 (depends on 2)

The compound of claim 2, wherein L100 is a divalent linker comprising
wherein R9 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 10 (depends on 2)

The compound of claim 2, wherein L100 is a divalent linker comprising
wherein R102 is unsubstituted C1-C4 alkyl.

### Claim 11 (depends on 2)

The compound of claim 2, wherein L100 is
-L101-L102-L103-L104-L105-;
wherein L101, L102, L103, L104, and L105 are independently a bond, —NH—, —O—,
—C(O)—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

### Claim 12 (depends on 2)

The compound of claim 2, wherein L100 is a divalent linker comprising:

### Claim 13 (depends on 2)

The compound of claim 2, wherein L100 is a divalent linker comprising:

### Claim 14 (depends on 2)

The compound of claim 2, wherein L100 is a divalent linker comprising:

### Claim 15 (depends on 2)

The compound of claim 2, wherein L100 is a divalent linker comprising

### Claim 16 (depends on 2)

The compound of claim 2, wherein L100 is a divalent linker comprising
wherein L2 is a bond or a divalent linker; and
R6 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2,
—CHI2, —CH3Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH,
—SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H,
—NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2,
—OCHI2, —OCHF2, —OCH3Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.

### Claim 17 (depends on 2)

The compound of claim 2, having the formula:
wherein L100 has the formula:

### Claim 18 (depends on 2)

The compound of claim 2, having the formula:
wherein L100 has the formula:

### Claim 19 (depends on 2)

The compound of claim 2, having the formula:
wherein L100 has the formula:

### Claim 20 (depends on 2)

The compound of claim 2, having the formula:
wherein L100 has the formula:
